BRPI0813630A2 - combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e) - Google Patents

combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)

Info

Publication number
BRPI0813630A2
BRPI0813630A2 BRPI0813630A BRPI0813630A BRPI0813630A2 BR PI0813630 A2 BRPI0813630 A2 BR PI0813630A2 BR PI0813630 A BRPI0813630 A BR PI0813630A BR PI0813630 A BRPI0813630 A BR PI0813630A BR PI0813630 A2 BRPI0813630 A2 BR PI0813630A2
Authority
BR
Brazil
Prior art keywords
cd49e
integrin
antibody
beta
alpha
Prior art date
Application number
BRPI0813630A
Other languages
English (en)
Inventor
Ramakrishnan Vanitha
Bhaskar Vinay
Original Assignee
Facet Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facet Biotech Corp filed Critical Facet Biotech Corp
Publication of BRPI0813630A2 publication Critical patent/BRPI0813630A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
BRPI0813630A 2007-07-27 2008-07-28 combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e) BRPI0813630A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95232807P 2007-07-27 2007-07-27
PCT/US2008/071379 WO2009018226A2 (en) 2007-07-27 2008-07-28 Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)

Publications (1)

Publication Number Publication Date
BRPI0813630A2 true BRPI0813630A2 (pt) 2019-09-24

Family

ID=40291258

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813630A BRPI0813630A2 (pt) 2007-07-27 2008-07-28 combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)

Country Status (9)

Country Link
US (1) US20090041767A1 (pt)
EP (1) EP2193148A2 (pt)
JP (1) JP2010534685A (pt)
KR (1) KR20100040877A (pt)
AU (1) AU2008282331A1 (pt)
BR (1) BRPI0813630A2 (pt)
CA (1) CA2694644A1 (pt)
MX (1) MX2010000997A (pt)
WO (1) WO2009018226A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255792A1 (en) * 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
CA2775601C (en) * 2009-09-28 2017-10-03 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
ES2699532T3 (es) * 2011-03-23 2019-02-11 Univ California Métodos y composiciones para mejorar la terapia antiangiogénica con anti-integrinas
KR20140135197A (ko) * 2012-02-16 2014-11-25 카프니아, 인코포레이티드 분산시키는 노우즈피스를 가진 가스 디스펜서
CN103656656A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 甲苯磺酸索拉非尼药物组合物及制备方法
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
JP7145503B2 (ja) * 2015-09-17 2022-10-03 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
EP3875102A1 (en) * 2015-09-17 2021-09-08 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
SG52215A1 (en) * 1992-02-19 1998-09-28 Schering Corp Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
ATE531388T1 (de) * 2004-03-24 2011-11-15 Abbott Biotherapeutics Corp Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
TWI397535B (zh) * 2006-03-21 2013-06-01 Genentech Inc 包含α5β1拮抗劑之組合治療
EA200802061A1 (ru) * 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма

Also Published As

Publication number Publication date
WO2009018226A2 (en) 2009-02-05
AU2008282331A1 (en) 2009-02-05
EP2193148A2 (en) 2010-06-09
KR20100040877A (ko) 2010-04-21
WO2009018226A3 (en) 2009-04-02
US20090041767A1 (en) 2009-02-12
CA2694644A1 (en) 2009-02-05
MX2010000997A (es) 2010-03-31
JP2010534685A (ja) 2010-11-11

Similar Documents

Publication Publication Date Title
BRPI0813630A2 (pt) combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)
BRPI0717367A2 (pt) Di-hidropirazolonas substituídas e sua aplicação.
DE602007014297D1 (de) Kontaktfreie Mehrbereichssonde
BRPI0811805A2 (pt) "artigo absorvente alongado e método para sua fabricação".
BRPI0714539A2 (pt) "formas farmacêuticas"
BRPI0807907A2 (pt) co-cristais e composições farmacêuticas compreendendo os mesmos.
BRPI0810928A2 (pt) "composição farmacêutica"
PL2054405T3 (pl) Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna
ATE517097T1 (de) Thiazol- und oxazolsubstituierte arylamide
FI20055150A (fi) Sakeuden muuttaminen ja mittaaminen
BRPI0920850A2 (pt) novos compostos e sua utilização
DK3181691T3 (da) Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina
FI20071030A0 (fi) Off-line -vastauskortti ja järjestely vastauksen kyselemiseksi vastauskortilta
ITMI20070437U1 (it) "baldacchino ad alta fedelta'"
UA14823S (uk) Кутовий диван-ліжко «зевс»
UA15095S (uk) Диван м'який «айленд»
UA14085S (uk) Комплект етикеток «kalganoff» настоянка»
UA14810S (uk) Диван «парадіз»
UA14052S (uk) Диван «256»
UA14055S (uk) Диван «806»
UA14058S (uk) Диван «243»
UA14229S (uk) Диван «Vitalistyle»
UA15122S (uk) Диван кутовий «марсель»
UA13956S (uk) Комплект етикеток «kalganoff» настоянка з клюквою»

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.